CureVac
CureVac is a global biopharmaceutical company specializing in the development of messenger RNA (mRNA) technology for innovative vaccines and therapeutics. Focused on advancing medical science, CureVac leverages its proprietary mRNA platform to design and produce novel treatments for infectious diseases, cancer, and rare conditions. The company’s research and development pipeline includes a range of clinical and preclinical programs aimed at addressing unmet medical needs. Committed to scientific excellence and collaboration, CureVac partners with leading organizations to accelerate the delivery of next-generation mRNA-based medicines. With a strong emphasis on safety, efficacy, and innovation, CureVac is dedicated to transforming the future of healthcare through cutting-edge biotechnology solutions.